Dupilumab brings nerve fibers back to life in eczema patients. A phase 4 exploratory study found that dupilumab restored intraepidermal nerve fiber density in moderate-to-severe atopic dermatitis patients to levels comparable to healthy individuals after just 16 weeks of treatment. The drug also significantly improved eczema severity and itch scores along the way.
A new phase 4 exploratory study has found that dupilumab doesn't just calm the skin — it may actually help rebuild it at the nerve level. Researchers from Germany and the US treated 31 adults with moderate-to-severe atopic dermatitis (AD) with dupilumab 300 mg every two weeks for 16 weeks, measuring intraepidermal nerve fiber density (IENFD) via skin biopsies before and after treatment.
The results were striking: patients who started with notably lower nerve fiber density than healthy controls ended up with levels nearly identical to those of healthy individuals by week 16. This suggests dupilumab may reverse some of the neurological skin damage associated with chronic AD, not just manage symptoms.
By the Numbers:
Why it matters: Nerve fiber loss in the skin is linked to chronic itch and impaired skin barrier function in AD. Demonstrating that dupilumab can restore IENFD to near-normal levels adds a new dimension to our understanding of how the drug works — and could support its use as a disease-modifying therapy, not just a symptom reliever.
